CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,534 | -44.0% | 33,786 | -30.8% | 0.00% | -33.3% |
| Q2 2023 | $2,739 | +23.1% | 48,803 | -0.8% | 0.01% | +20.0% |
| Q1 2023 | $2,225 | -30.6% | 49,204 | -37.6% | 0.01% | -37.5% |
| Q4 2022 | $3,204 | -99.8% | 78,816 | +212.7% | 0.01% | +60.0% |
| Q3 2022 | $1,648,000 | +28.8% | 25,208 | +19.7% | 0.01% | +66.7% |
| Q2 2022 | $1,280,000 | +74.6% | 21,064 | +80.3% | 0.00% | +200.0% |
| Q1 2022 | $733,000 | -78.4% | 11,682 | -71.1% | 0.00% | -85.7% |
| Q4 2021 | $3,400,000 | +1526.8% | 40,384 | +2061.9% | 0.01% | – |
| Q3 2021 | $209,000 | -67.3% | 1,868 | -52.8% | 0.00% | -100.0% |
| Q2 2021 | $640,000 | +103.2% | 3,956 | +53.2% | 0.00% | 0.0% |
| Q1 2021 | $315,000 | +27.5% | 2,583 | +60.3% | 0.00% | 0.0% |
| Q4 2020 | $247,000 | – | 1,611 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |